Akreos Posterior Chamber Intraocular Lens
Bausch + Lomb, Inc. · Decision date Sep 30, 2025
What did the FDA decide?
FDA records P060022/S037 as a supplement to PMA P060022, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 30, 2025.
FDA approval order statement
adding a second component supplier for a component of the primary packaging for the non-preloaded Akreos family of intraocular lenses (IOLs)
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 30, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P060022/S037
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- Decision code
- OK30
- Decision date
- Sep 30, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P060022. Subsequent supplements may change the device or its indications.
FDA decision timeline
P060022 · Original PMA
AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS,MODEL ADAPT
P060022/S036 · Related supplement
Akreos Posterior Chamber Intraocular Lens (IOL)
P060022/S037 received
Application receipt date recorded by FDA.
P060022/S037 · FDA decision
30-Day Notice
P060022/S038 · Related supplement
Akreos posterior chamber intraocular lens
Timeline entries are records held by MedtechLedger for P060022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P060022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA approval | Sep 5, 2008 | FDA | |
Akreos Posterior Chamber Intraocular Lens (IOL)P060022/S036 | Bausch + Lomb, Inc. | PMA supplement | Jul 22, 2025 | FDA |
Akreos posterior chamber intraocular lensP060022/S038 | Bausch + Lomb, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 50 Technology Dr., Irvine, CA, 92618
Sources and methodology
- Original FDA record: P060022/S037
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




